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An AAVP-based solid-phase transducing matrix for transgene
delivery: potential for translational applications
TL Smith1,2, GR Souza3,4, RL Sidman5, W Arap1,6,7 and R Pasqualini1,2,7
A hybrid vector of adeno-associated virus and phage (termed AAVP) has been introduced as a platform for systemic ligand-directed
delivery of transgenes to tumors over the past decade. A series of studies have evaluated the AAVP platform for potential
theranostic or purely therapeutic applications in several tumor models. Sufﬁcient ligand-directed tumor targeting consistently
resulted in speciﬁc molecular-genetic imaging and/or anti-tumor responses to ‘suicide’ transgene delivery. However, efforts to
optimize transduction efﬁciency are still ongoing. Here, we set out to expand the translational utility of AAVP by combining it with
gold (Au) nanoparticles in order to generate a ‘transducing matrix’ for improved targeted gene delivery in solid phase. Targeted
AAVP-based solid-phase transduction is superior to conventional transduction in soluble (aqueous) environments. This transducing
matrix is stable and can be further modiﬁed with additional attributes (for example, magnetization) for targeted imaging and
therapeutic gene delivery. Notably, it spontaneously assembles around cells in vitro to markedly enhance transduction capabilities
compared with AAVP alone. This versatile nanoplatform may enable new applications of AAVP for transgene delivery in
translational settings including, for example, efforts toward complex tissue patterning.
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INTRODUCTION
The pIII coat protein of bacteriophage (phage) can be modiﬁed to
display peptide ligands that are selected to home to a correspond-
ing target receptor on a desired cell population. Such a targeting
attribute has great potential for clinical applications including gene
therapy approaches, particularly against cancer. Indeed, in the
decade since phage was ﬁrst combined with AAV to yield AAVP
(adeno-associated virus and phage),1 which has a high transduction
efﬁciency for human cells, numerous constructs have been tested
for theranostic and therapeutic applications in preclinical cancer
models.2–8 Phage particles have also been more recently combined
with gold (Au) nanoparticles to generate a nanoscaffold that self-
assembles spontaneously as a result of the physical and biological
properties of its various components.9,10 These aggregates are stable
fractal networks with high surface area, formed from electrostatic
interactions between amino acids on the phage pVIII capsid proteins
and the dispersed Au nanoparticles and subject to ﬂuctuations in
phage input, pH and salt concentration, which, when optimized, can
minimize Au agglomeration and maximize network stability.9,10 The
properties of these peptide-targeted scaffolds can be further tuned
for translational applications by introducing various functional
nanoparticles, including additional elements such as imidazole to
adjust the optical properties,9 iron oxide to generate magnetic
ﬁelds11 and liposomes loaded with therapeutic or imaging cargo.12
Here, we hypothesized that including AAVP (as opposed to phage
particles alone) in these nanoscaffolds would generate a stable,
modiﬁable matrix that would transduce mammalian cells with
higher efﬁciency and thereby improve transgene delivery in several
settings.
RESULTS
As a proof-of-concept, we evaluated the efﬁcacy of the self-
assembled transducing matrix in cells growing in tissue culture.
First, an AAVP displaying the double-cyclic RGD-4C ligand motif
(sequence CDCRGDCFC) and carrying a green ﬂuorescent
protein-encoding transgene under the control of a standard
CMV promoter13 served to form the nanoscaffold and was
administered to cells in culture (Figure 1). The nanoscaffold was
formed as described9–11 but with increasing amounts of AAVP
particles substituted for phage particles. In our academic and
commercial pipeline, after common citrate reduction using Au
(III) chloride (⩾99.99%, Sigma-Aldrich, St. Louis, MO, USA), Au
nanoparticles used in scaffold formation are consistently 45–50
nm.9–11 Although RGD-4C phage is ~ 6 nm in diameter and just
under 1 μm in length, the inclusion of an AAV genomic cassette
into the phage genome appears to increase the resulting hybrid
particle length,9,14 with no detectable differences in scaffold
properties. At all amounts measured and conditions evaluated,
the transduction efﬁciency was substantially higher by using the
transducing matrix relative to AAVP alone. We have previously
demonstrated that incubating cells with an Au-phage scaffold
result in strong accumulation of a molecular network in the cells
that remains even after washings.9 This empiric biologic
phenomenon likely leads to retention in and around the cells,
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resulting in a greater percent of transduced cells by using the
AAVP-based transducing matrix compared to AAVP alone.
Additionally, previous work has shown that the combination of
Au nanoparticles and RGD-4C phage particles produces an
aggregate network that is relatively ‘loose,’ with a lower fractal
dimension than more compact imidazole-containing constructs,
exposing binding sites and producing a distinct kinetic proﬁle
that results in cellular internalization.9 This increased internali-
zation efﬁciency compared to other scaffold formulations are
retained here, and such receptor-mediated cell internalization is
critical for targeted AAVP transduction. Although these experi-
mental conditions may certainly be further optimized, the proof-
of-concept studies presented here reveal a novel nanoengineer-
ing platform for biological investigation and development into
translational applications.
DISCUSSION
Recently, a phage-based scaffold was evaluated for its translational
potential in several animal models.12 Targeting activity was
conﬁrmed in vivo, revealing tumor homing and scaffold aggregation
prior to cargo delivery, and, because components of the networks
can be imaged independently, this scaffold should provide a
unique, biocompatible tool for enhanced gene expression. In
addition to the utility of this nanoscaffold for peptide-guided
therapeutic gene delivery and reporter gene imaging, the integra-
tion of additional biocompatible nanoparticles, such as silicon (Si) or
iron (FeO),11 into the transducing matrix could yield further practical
applications including signal reporters and/or temperature sensors.
Optimizing AAVP input in relation to transduction efﬁciency during
preclinical studies could yield many translational implications.
Moreover, because of its greater transduction efﬁciency in vitro
compared to AAVP alone, the utility of the transducing matrix as a
screening tool to validate ligands and identify susceptible cell lines
for future studies should become evident. Indeed, incorporation of
alternate nanoparticles for gene transduction in solid phase would
likely provide a uniquely engineered platform for imaging
(ﬂuorescence, darkﬁeld or magnetic resonance imaging) or other
signal reporting (surface-enhanced Raman scattering, SERS), and
even tunable photon-to-heat conversion.9,12,15 Finally, theranostic
applications for AAVP are being investigated more frequently now
that the technology has matured.7,8 We have already begun
optimizing the vector itself for speciﬁc tumor types and their
corresponding molecular markers. By incorporating tumor-speciﬁc
promoters for transcriptional targeting8 and rationally chosen motifs
for ligand–receptor-directed targeting,4 we have moved AAVP from
a preclinical tool toward an enabling solid-phase platform with
tantalizing translational ramiﬁcations. Speciﬁcally, this initial brief
report outlines the critical optimization of transduction efﬁciency in
solid phase with demonstrably superior efﬁcacy compared to AAVP
alone, potentially increasing clinical utility, although simultaneously
enabling tumor trafﬁcking and accumulation to be monitored,
which is useful for a repetitive dosing schedule, because Au
nanoparticles are biocompatible and distinguishable by X-ray-based
imaging including computed tomography. Although one type of
AAVP vectors contains a theranostic reporter transgene suitable for
both imaging and therapy after administration of an appropriate
substrate,1,2,5,7,8 a second type of AAVP is being pursued with a
cytokine transgene not amenable to imaging,3,4,6 which could be
directly imaged by using a transducing matrix. In vivo studies will be
critical for evaluating these translational transducing matrix proper-
ties. Further arguments could be made that the transducing matrix
is particularly suitable for tissue engineering in which multiple types
of cells would have to be transduced in a pattern to form complex
three-dimensional matrices. Rather than direct immobilization of
viral particles alone to encourage transduction, the inclusion of
magnetic particles would restrict accessibility to cells in speciﬁc
patterns or spatial conﬁnes, while receptor expression proﬁles
enable molecularly permissive transduction of ligand-directed
particles. Within the context of the ﬁrst decade and beyond from
the introduction of targeted AAVP as a viable man-made
mammalian cell-transducing viral particle, the new results intro-
duced here further highlight some of the potential of this
technology at large.
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Figure 1. Comparison of adeno-associated virus and phage (AAVP) alone and AAVP and gold (Au) nanoparticles in the transducing matrix in
solid phase. (a) Green ﬂuorescent protein (GFP) expression (green) in KS1767 Kaposi sarcoma cells incubated with targeted or insertless
control AAVP alone or the corresponding transducing matrices. (b) Relative quantiﬁcation of transduced cells after incubation with either
targeted or insertless (negative control) AAVP alone or in a transducing matrix construct.
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